176 related articles for article (PubMed ID: 34498314)
1. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy.
Kirchgesner J; Desai RJ; Schneeweiss MC; Beaugerie L; Kim SC; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2022 Feb; 31(2):167-175. PubMed ID: 34498314
[TBL] [Abstract][Full Text] [Related]
2. Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Kim SC; Schneeweiss S
Clin Pharmacol Ther; 2022 Jan; 111(1):179-186. PubMed ID: 34027993
[TBL] [Abstract][Full Text] [Related]
3. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Kirchgesner J; Desai RJ; Schneeweiss MC; Beaugerie L; Schneeweiss S; Kim SC
Gut; 2022 Sep; 71(9):1781-1789. PubMed ID: 35387877
[TBL] [Abstract][Full Text] [Related]
4. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis.
Spoendlin J; Desai RJ; Franklin JM; Glynn RJ; Payne E; Schneeweiss S
Clin Pharmacol Ther; 2020 Oct; 108(4):874-884. PubMed ID: 32320482
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
8. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
14. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
16. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 May; 61(5):382-390. PubMed ID: 32390361
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
[TBL] [Abstract][Full Text] [Related]
18. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.
Kobayashi T; Udagawa E; Uda A; Hibi T; Hisamatsu T
J Gastroenterol Hepatol; 2020 Feb; 35(2):225-232. PubMed ID: 31397010
[TBL] [Abstract][Full Text] [Related]
19. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
20. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
